BSD Medical Announces that Dr. Rüdiger Wessalowski has been Awarded the
ESHO-BSD Award 2013 for his Pioneering Work in Hyperthermia Research
SALT LAKE CITY -- July 25, 2013
BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today
that the ESHO-BSD Award for 2013 was awarded to Dr. Rüdiger Wessalowski in
recognition of his pioneering work in the field of hyperthermia research. The
award was presented at the annual meeting of the European Society for
Hyperthermic Oncology (ESHO), which was held in Munich, June 19 to 22, 2013.
Dr. Wessalowski is an Associate Professor at the renowned Paediatric Oncology
Clinic, Haematology and Immunology, Centre for Child and Adolescent Health,
Heinrich-Heine University, Dusseldorf, Germany. Dr. Wessalowski led the
multidisciplinary research team from the authoritative MAKEI study group that
conducted the seminal study on the addition of hyperthermia to chemotherapy to
treat children and adolescents with recurrent germ cell tumors.
The study, which was published in the prestigious The Lancet Oncology,
demonstrated significantly improved survival from the addition of hyperthermia
to chemotherapy. (Rüdiger Wessalowski et al.; The Lancet Oncology, Early
Online Publication, July 1, 2013, doi: 10.1016/S1470-204570271-7.) As part
of this study, the research team established a treatment protocol that would
allow clinicians to provide a long-term cure for most of these patients who
have a very poor prognosis. The published study demonstrated an objective
tumor reduction in 86% of the patients, with a 5-year overall survival rate of
72%, which is unmatched by any other clinical report on recurrent childhood
malignant germ-cell tumors. This study also showed that hyperthermia activated
chemotherapy drugs that had previously failed these patients.
"Dr. Wessalowski deserves appreciation and recognition for his remarkable
achievements that have benefited society," said Harold Wolcott, BSD President.
"His emphasis on making hyperthermia treatment for children and adolescents a
quantifiable therapy will significantly influence how hyperthermia will be
practiced in the future."
Dr. Wessalowski studied medicine in Dusseldorf and is the senior physician at
the Paediatric Oncology Clinic, Haematology and Immunology, Centre for Child
and Adolescent Health, Heinrich-Heine University, Dusseldorf, German. Dr.
Wessalowski is focused on clinical research into new treatments using
hyperthermia for the treatment of children and adolescents suffering from
malignant tumors that have relapsed or not responded to standard therapies.
About ESHO and the ESHO-BSD Award
The aim of the European Society for Hyperthermic Oncology (ESHO) is the
promotion of research in physics, engineering, biology and medicine to
clinical application of hyperthermia in cancer therapy. This professional
society was founded in England in 1987 and currently has its headquarters in
Rotterdam, Netherlands. The ESHO-BSD Award is presented yearly to one of the
members of ESHO who has made valuable contributions to the field of
hyperthermia. The beneficiary of the award is determined each year by a select
group of former award recipients.
About the BSD-2000 Hyperthermia System
The BSD-2000 – developed and patented exclusively by BSD – delivers localized
therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The
BSD-2000 creates a central focusing of energy that can be electronically
focused to target the shape, size and location of the tumor, thus providing
dynamic control of the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and
Drug Administration (FDA) for use in conjunction with radiation therapy for
the treatment of cervical cancer patients who are ineligible for chemotherapy.
The BSD-2000 also has CE (Conformité Européenne) Marking approval for the
commercial sale in Europe. CE Marking approval is also recognized in many
countries outside of the EU.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including the expected use of proceeds relating to the
recently completed offering. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.
BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
Press spacebar to pause and continue. Press esc to stop.